Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Fig. 5

Distribution of methylation mark IHC scores in PC and NM tissue samples. Histograms show the distribution of samples with strong (score > 1; black boxes), moderate (score = 1; dark gray boxes), or weak (score < 1; light gray boxes) immunoreactivity for each methylation mark. a Distribution of 5mC scores in NM and PC samples from the full cohort, and in ERG− and ERG+ PC samples (two patients had unknown ERG status). b Distribution of 5hmC scores in NM and PC samples from the full cohort, and in ERG− and ERG+ PC samples. c Distribution of 5fC scores in NM and PC samples from the full cohort, and in ERG− and ERG+ PC samples (eight patients had unknown ERG status). d Distribution of 5caC scores in NM and PC samples from the full cohort, and in ERG− and ERG+ PC samples (four patients had unknown ERG status). Significant p values (chi2 test) are marked by an asterisk (*)

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us